WhiteOak Capital Pharma and Healthcare Fund

SectoralDirect and Regular plans, Growth option

Data as on 30-10-2026

WhiteOak Capital Pharma and Healthcare Fund is a Sectoral fund run by WhiteOak Capital Mutual Fund. On 30-09-2026, it managed ₹927 Cr of investors' money. In the year to 30-10-2026, its Direct plan returned 19.5% and its Regular plan returned 17.5%. Its benchmark, BSE Healthcare TRI, returned 12.4% over the same year.

NAV (Direct plan): ₹17.44; ▲ 0.86%30-10-2026
NAV (Regular plan): ₹16.63; ▲ 0.86%30-10-2026
Expense ratio: 1.07%Direct2.75%Regular; 1.07%; A year
Riskometer: Very High; Set by the fund house
1 year return: 19.5%Direct17.5%Regular; 19.5%; Total

WhiteOak Capital Pharma and Healthcare Fund NAV Today

NAV on 30-10-2026: Direct Plan Growth ₹17.44 (up 0.86% that day); Regular Plan Growth ₹16.63 (up 0.86% that day).

This fund (Direct plan)

₹17.441

WhiteOak Capital Pharma and Healthcare Fund Returns vs BSE Healthcare TRI

Returns as on 30-10-2026. Up to one year they are absolute returns. Longer periods are a rate per year.

Trailing returns
Period	1M	3M	6M	1Y	3Y	5Y	10Y
This fund (Direct)	+0.92%	+1.33%	+17.99%	+19.53%	--	--	--
This fund (Regular)	+0.78%	+0.87%	+16.96%	+17.49%	--	--	--
BSE Healthcare TRI	+0.24%	−0.99%	+12.80%	+12.37%	+23.01%	+15.61%	+12.48%
Sectoral average	−1.70%	−4.49%	+2.30%	−0.58%	--	--	--
Best in Sectoral	+7.03%	+2.10%	+17.99%	+19.53%	--	--	--
Worst in Sectoral	−7.36%	−8.92%	−7.57%	−9.47%	--	--	--
Rank in Sectoral	3/20	2/19	1/19	1/17	--	--	--

Category rows compare the Direct plans of 20 Sectoral funds. Rank 1 is the highest return.

WhiteOak Capital Pharma and Healthcare Fund Year-wise Returns

Return of each calendar year
Year	Direct	Regular	BSE Healthcare TRI
2026to date	+22.83%	+21.08%	+15.08%
2025	+1.84%	+0.09%	−2.72%

WhiteOak Capital Pharma and Healthcare Fund Rolling Returns

The return of every holding period in the fund's history, not only the one that ends today

Rolling returns

Each point is the yearly return of one 1-year holding period, plotted on the day it ended. There are 424 periods, one for each trading day from 07-02-2025 to 30-10-2026.

−10%0%10%20%30%40%

Mar 2024
to
Mar 2025Jul 2024
to
Jul 2025Oct 2024
to
Oct 2025Feb 2025
to
Feb 2026May 2025
to
May 2026Sept 2025
to
Sept 2026

WhiteOak Capital Pharma and Healthcare Fund (Direct)BSE Healthcare TRI

Every holding period at a glance

Period	Periods	Median	Lowest	Highest	With a loss	Benchmark median	Beat benchmark
1 year	424	18.4%	0.6%	35.5%	0%	11.0%	100%
2 years	178	20.3%	11.1%	25.7%	0%	12.3%	100%

Period	Periods	Median	Lowest	Highest	With a loss	Benchmark median	Beat benchmark
1 year	21	14.7%	−2.4%	38.5%	10%	7.9%	100%

Lumpsum: the yearly rate (CAGR) from the NAV on a period's first day to the NAV on its last. SIP: the XIRR of the monthly instalments and their value on the last day. "With a loss" counts the periods that ended below the money put in. "Beat benchmark" counts the periods in which the fund did better than BSE Healthcare TRI over the same days. Past returns do not promise future returns.

WhiteOak Capital Pharma and Healthcare Fund Risk

How much it swings, and the falls an investor had to sit through

Risk and return

Measure	WhiteOak Capital Pharma and Healthcare Fund (Direct)This fund	BSE Healthcare TRI
Return (CAGR)	+19.53%	+12.37%
Standard deviation	13.75%	13.56%
Sharpe ratio	1.04	0.53
Sortino ratio	1.57	0.77
Maximum drawdown	−9.8% (23-10-2026)	−9.9% (23-10-2026)
Beta	0.97	1.00
Alpha	+7.36%	0.00%

From daily NAVs, 30-10-2025 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta: 1 moves with the benchmark, below 1 moves less. Alpha: return beyond what its beta explains, a year.

Measure	WhiteOak Capital Pharma and Healthcare Fund (Direct)This fund	BSE Healthcare TRI
Return (CAGR)	+22.30%	+15.00%
Standard deviation	14.35%	14.24%
Sharpe ratio	1.14	0.64
Sortino ratio	1.62	0.89
Maximum drawdown	−15.4% (28-02-2025)	−16.2% (28-02-2025)
Beta	0.97	1.00
Alpha	+7.59%	0.00%

From daily NAVs, 07-02-2024 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta: 1 moves with the benchmark, below 1 moves less. Alpha: return beyond what its beta explains, a year.

Drawdowns

How far below its previous high each one was on every day: the falls an investor had to sit through. 0% means it was at a new high.

−20%−15%−10%−5%0%

20252026

WhiteOak Capital Pharma and Healthcare Fund (Direct)BSE Healthcare TRI

	Worst fall	High before it	Bottom	Back at the high	Time to climb back	Below its high today
WhiteOak Capital Pharma and Healthcare Fund (Direct)	−15.4%	02-01-2025	28-02-2025	14-07-2025	4 months	−3.0%
BSE Healthcare TRI	−16.2%	02-01-2025	28-02-2025	29-07-2025	5 months	−3.8%

From the Direct plan's daily NAV since 07-02-2024, adjusted for unit splits, and BSE Healthcare TRI over the same days. "Time to climb back" runs from the bottom to the first day back at the old high.

WhiteOak Capital Pharma and Healthcare Fund vs Other Sectoral Funds

The five Sectoral funds with the best three year return, and this fund. Direct plans.

Fund name	Rank	AUM (Cr)	Exp. ratio	1Y return	3Y return	3Y alpha	3Y beta	3Y Sharpe	3Y Sortino
DSP Healthcare Fund	1/9	3,750	0.76%	+15.40%	+21.77%	+2.89%	0.77	1.25	1.77	Compare
WhiteOak Capital Pharma and Healthcare Fund	1/17	927	1.07%	+19.53%	--	--	--	--	--
Nippon India Pharma Fund	2/9	9,166	0.99%	+9.05%	+18.56%	−2.50%	0.88	0.97	1.39	Compare
Bandhan Transportation and Logistics Fund	3/9	771	1.07%	−1.82%	+17.11%	+1.71%	0.84	0.69	0.97	Compare
Nippon India Power & Infra Fund	4/9	7,867	1.11%	−2.17%	+16.41%	+2.80%	0.97	0.59	0.78	Compare
Invesco India Financial Services Fund	5/9	1,789	0.96%	−2.22%	+15.03%	+5.53%	0.93	0.55	0.77	Compare

AUM is each fund's size at the end of its last reported month, from its own portfolio file. We calculate the risk ratios from daily NAVs over the last three years. The risk-free return is what NSE's overnight rate index earned over the same years. Alpha and beta compare each fund with its own benchmark's TRI. "--" means we have no figure: for alpha and beta, no daily series for that benchmark.

WhiteOak Capital Pharma and Healthcare Fund Expense Ratio and Costs

What each plan charges a year, in force from 23-10-2026

Plan	Base expense ratio	Brokerage	Transaction costs	Levies and GST	Total expense ratio	Sectoral median	Cost rank (1 = cheapest)
Direct	0.54%	0.12%	0.01%	0.40%	1.07%	1.07%	9/20
Regular	1.96%	0.12%	0.01%	0.66%	2.75%	2.51%	15/20

The expense ratio comes out of the fund's assets every day, so every return on this page is already after it. Base expense ratio: the fund house's own fee. The total adds brokerage, the cost of executing trades, and statutory levies with GST. From AMFI's expense ratio file. Cost rank: where this plan comes when the Sectoral funds' plans of the same type are sorted from the lowest total expense ratio to the highest.

Direct vs Regular: what the gap cost

Both plans own the same portfolio, so the difference in what they earned is the Regular plan's extra cost, taken out of its NAV.

Over the last	Regular	Direct	Direct earned more by	₹1 lakh became (Regular)	₹1 lakh became (Direct)
1 year	17.49%	19.53%	2.04%	₹1,17,490	₹1,19,530

Returns over more than 1 year are a rate a year (CAGR). ₹1 lakh invested once at the start of each period, valued on the last NAV.

WhiteOak Capital Pharma and Healthcare Fund SIP Calculator

What a one-time or monthly investment in this fund would be worth today, from its own NAV history

Growth of an investment

Every month₹

Step up each year

PeriodFor

₹10,000 on the first trading day of every month, from 07-02-2024 to 30-10-2026: 33 instalments, ₹3,30,000 in all.

Investment	Invested	Value now	Gain	Return a year
Direct planWhiteOak Capital Pharma and Healthcare Fund (Direct)	₹3,30,000	₹4,37,625	₹1,07,625	21.2%
Regular planWhiteOak Capital Pharma and Healthcare Fund (Regular)	₹3,30,000	₹4,26,281	₹96,281	19.1%
BSE Healthcare TRI	₹3,30,000	₹3,95,351	₹65,351	13.3%
Category averageCategory average, 20 Sectoral funds	₹3,30,000	₹3,57,680	₹27,680	5.8%

₹0₹1.0 L₹2.0 L₹3.0 L₹4.0 L₹5.0 L

20252026

Direct planWhiteOak Capital Pharma and Healthcare Fund (Direct)Regular planWhiteOak Capital Pharma and Healthcare Fund (Regular)BSE Healthcare TRICategory averageCategory average, 20 Sectoral fundsAmount invested

From each plan's published NAV (Growth option), the benchmark's TRI and the category average, over the same days. Return a year: XIRR for a SIP, CAGR for a lumpsum, shown for a year or more. It does not include exit load, stamp duty or tax. Past returns do not promise future returns.

WhiteOak Capital Pharma and Healthcare Fund Asset Allocation

Asset allocation as on 30-09-2026

What the fund holds

90.7%Equity

Asset	Fund	Category
Equity	90.7%	95.6%
Cash and others	6.1%	3.7%
Debt	3.1%	0.7%

Market cap of stocks

Market cap	Fund	Category
Large Cap	29.2%	44.1%
Mid Cap	21.7%	21.8%
Small Cap	37.5%	26.9%
Not on AMFI's list	2.4%	2.3%

Share of the whole fund. Category: the average of the Sectoral funds that hold stocks. Groups follow AMFI's latest list, as SEBI defines them: Large Cap is the 100 largest companies, Mid Cap the next 150, Small Cap the rest.

WhiteOak Capital Pharma and Healthcare Fund Sector Allocation

Sector allocation of the fund's stocks as on 30-09-2026

Largest sectors

Pharmaceuticals & Biotechnology61.2%
Healthcare Services23.0%
Chemicals & Petrochemicals3.3%
Consumer Durables1.8%
Healthcare Equipment & Supplies1.4%

Sector changes

Sector	July 2026	August 2026	September 2026	Change
Pharmaceuticals & Biotechnology	59.8%	59.4%	61.2%	+1.4%
Healthcare Services	28.4%	26.9%	23.0%	−5.4%
Chemicals & Petrochemicals	3.8%	3.4%	3.3%	−0.5%
Consumer Durables	1.4%	2.0%	1.8%	+0.4%
Healthcare Equipment & Supplies	1.1%	2.0%	1.4%	+0.3%

Each sector's share of the fund at the end of each month. The five largest sectors of September 2026. Change: from July 2026 to September 2026, in % of the fund.

WhiteOak Capital Pharma and Healthcare Fund Portfolio Holdings

As on 30-09-2026 · 59 holdings · from the fund house's monthly portfolio

Holdings	Sector / Rating	Weight%	1M change
Divi's Laboratories Limited	Pharmaceuticals & Biotechnology	8.36%	+3.6%
Sun Pharmaceutical Industries Limited	Pharmaceuticals & Biotechnology	7.11%	+7.8%
Torrent Pharmaceuticals Limited	Pharmaceuticals & Biotechnology	6.26%	0.0%
Laurus Labs Limited	Pharmaceuticals & Biotechnology	3.91%	+2.6%
Apollo Hospitals Enterprise Limited	Healthcare Services	3.75%	−11.2%
Cipla Limited	Pharmaceuticals & Biotechnology	3.68%	+21.5%
Sai Life Sciences Limited	Pharmaceuticals & Biotechnology	3.28%	−3.0%
IPCA Laboratories Limited	Pharmaceuticals & Biotechnology	2.88%	+13.9%
Zydus Lifesciences Limited	Pharmaceuticals & Biotechnology	2.81%	+11.9%
Neuland Laboratories Limited	Pharmaceuticals & Biotechnology	2.60%	0.0%
Dr. Lal Path Labs Limited	Healthcare Services	2.35%	0.0%
Corona Remedies Limited	Pharmaceuticals & Biotechnology	2.34%	0.0%
Thyrocare Technologies Limited	Healthcare Services	2.27%	+14.5%
Aurobindo Pharma Limited	Pharmaceuticals & Biotechnology	2.09%	0.0%
Ajanta Pharma Limited	Pharmaceuticals & Biotechnology	2.01%	+19.6%
Krishna Institute Of Medical Sciences Limited	Healthcare Services	1.85%	0.0%
Shaily Engineering Plastics Limited	Consumer Durables	1.84%	0.0%
Max Healthcare Institute Limited	Healthcare Services	1.84%	−30.4%
Global Health Limited	Healthcare Services	1.82%	+5.4%
Narayana Hrudayalaya Limited	Healthcare Services	1.61%	0.0%
Anthem Biosciences Limited	Pharmaceuticals & Biotechnology	1.57%	0.0%
Vijaya Diagnostic Centre Limited	Healthcare Services	1.56%	+6.5%
Onesource Specialty Pharma Limited	Pharmaceuticals & Biotechnology	1.55%	+57.3%
Acutaas Chemicals Limited	Pharmaceuticals & Biotechnology	1.45%	0.0%
Navin Fluorine International Limited	Chemicals & Petrochemicals	1.41%	0.0%
Fortis Healthcare Limited	Healthcare Services	1.36%	0.0%
Aarti Pharmalabs Limited	Pharmaceuticals & Biotechnology	1.20%	0.0%
Mankind Pharma Limited	Pharmaceuticals & Biotechnology	1.20%	New
Procter & Gamble Health Limited	Pharmaceuticals & Biotechnology	1.18%	0.0%
Rainbow Childrens Medicare Limited	Healthcare Services	1.15%	0.0%
Molbio Diagnostics Limited	Healthcare Equipment & Supplies	1.15%	0.0%
Piramal Pharma Limited	Pharmaceuticals & Biotechnology	1.06%	New
Aether Industries Limited	Chemicals & Petrochemicals	1.05%	+10.9%
Kovai Medical Center and Hospital Limited	Healthcare Services	0.95%	0.0%
Gland Pharma Limited	Pharmaceuticals & Biotechnology	0.93%	+11.5%
Senores Pharmaceuticals Limited	Pharmaceuticals & Biotechnology	0.80%	0.0%
Jupiter Life Line Hospitals Limited	Healthcare Services	0.73%	0.0%
Supriya Lifescience Limited	Pharmaceuticals & Biotechnology	0.69%	0.0%
Vimta Labs Limited	Healthcare Services	0.67%	0.0%
Innova Captab Limited	Pharmaceuticals & Biotechnology	0.63%	0.0%
91 Days Tbill (MD 03/12/2026) · Treasury bill	Sovereign	0.60%
91 Days Tbill (MD 05/11/2026) · Treasury bill	Sovereign	0.60%
Nephrocare Health Services Ltd	Healthcare Services	0.57%	0.0%
91 Days Tbill (MD 10/12/2026) · Treasury bill	Sovereign	0.53%
Manipal Health Enterprises Ltd	Healthcare Services	0.52%	−50.0%
182 Days Tbill (MD 05/11/2026) · Treasury bill	Sovereign	0.47%
Sudeep Pharma Limited	Chemicals & Petrochemicals	0.46%	0.0%
Tatva Chintan Pharma Chem Limited	Chemicals & Petrochemicals	0.42%	0.0%
Biocon Limited	Pharmaceuticals & Biotechnology	0.42%	0.0%
Orchid Pharma Limited	Pharmaceuticals & Biotechnology	0.41%	0.0%
Zota Health Care Limited	Pharmaceuticals & Biotechnology	0.40%	0.0%
91 Days Tbill (MD 29/10/2026) · Treasury bill	Sovereign	0.37%
91 Days Tbill (MD 19/11/2026) · Treasury bill	Sovereign	0.32%
Novartis India Limited	Pharmaceuticals & Biotechnology	0.24%	New
Laxmi Dental Limited	Healthcare Equipment & Supplies	0.23%	0.0%
91 Days Tbill (MD 22/10/2026) · Treasury bill	Sovereign	0.17%
Bharat Parenterals Limited	Pharmaceuticals & Biotechnology	0.10%	+99.4%
182 Days Tbill (MD 12/11/2026) · Treasury bill	Sovereign	0.08%
364 Days Tbill (MD 12/11/2026) · Treasury bill	Sovereign	0.01%

WhiteOak Capital Pharma and Healthcare Fund Stocks Bought and Sold

All changes are between August 2026 and September 2026

Stocks bought and sold in September 2026

Divi's Laboratories Limited	Added	+3.6%	8.36%
Sun Pharmaceutical Industries Limited	Added	+7.8%	7.11%
Apollo Hospitals Enterprise Limited	Reduced	−11.2%	3.75%
Laurus Labs Limited	Added	+2.6%	3.91%
Cipla Limited	Added	+21.5%	3.68%
Sai Life Sciences Limited	Reduced	−3.0%	3.28%
Max Healthcare Institute Limited	Reduced	−30.4%	1.84%
IPCA Laboratories Limited	Added	+13.9%	2.88%
Zydus Lifesciences Limited	Added	+11.9%	2.81%
Thyrocare Technologies Limited	Added	+14.5%	2.27%
Ajanta Pharma Limited	Added	+19.6%	2.01%
Global Health Limited	Added	+5.4%	1.82%
Vijaya Diagnostic Centre Limited	Added	+6.5%	1.56%
Onesource Specialty Pharma Limited	Added	+57.3%	1.55%
Mankind Pharma Limited	New	New	1.20%
Manipal Health Enterprises Ltd	Reduced	−50.0%	0.52%
Pfizer Limited	Sold out	−100%	was 1.14%
Piramal Pharma Limited	New	New	1.06%
Aether Industries Limited	Added	+10.9%	1.05%
Gland Pharma Limited	Added	+11.5%	0.93%
Poly Medicure Limited	Sold out	−100%	was 0.76%
Novartis India Limited	New	New	0.24%
Cohance Lifesciences Limited	Sold out	−100%	was 0.21%
Bharat Parenterals Limited	Added	+99.4%	0.10%

A change is counted by the number of shares the fund holds, not by price. A stock can become a smaller part of the fund in a month when the fund bought more of it, if its price fell. Debt papers are left out.

What WhiteOak Capital Pharma and Healthcare Fund bought and sold

WhiteOak Capital Pharma and Healthcare Fund Portfolio Overlap

Funds with the most similar portfolios, across every fund house and category

Fund	Overlap	Holdings in common
SBI Healthcare Opportunities FundThematic · SBI	57.6%	27	Compare
Mirae Asset Nifty 500 Healthcare ETFETF · Mirae Asset	57.4%	27	Compare
Bandhan BSE Healthcare Index FundIndex · Bandhan	54.7%	41	Compare
Motilal Oswal BSE Healthcare ETFETF · Motilal Oswal	54.5%	41	Compare
Mirae Asset Healthcare FundThematic · Mirae Asset	53.8%	20	Compare
ITI Pharma and Healthcare FundThematic · ITI	53.6%	22	Compare
Kotak Healthcare FundThematic · Kotak Mahindra	53.0%	23	Compare
Bajaj Finserv Healthcare FundThematic · Bajaj Finserv	52.2%	21	Compare

Overlap: for each holding both funds own, the smaller of its two weights, added up. 40% means 40% of each fund's money sits in positions the other also holds. From each fund's latest monthly portfolio, matched by ISIN. Cash and hedged positions are left out. Funds that overlap under 10% are not listed. A high overlap does not make two funds the same: their costs, lock-in and category can differ.

WhiteOak Capital Pharma and Healthcare Fund Overview

Fund facts from the scheme summary document, as on 16-10-2026

Expense ratio (Direct): 1.07%
Expense ratio (Regular): 2.75%
Category: Sectoral
Risk: Very High
Benchmark: BSE Healthcare TRI
Launch date: 06-02-2024
Minimum investment: ₹500
Minimum additional investment: ₹500
AUM: ₹926.55 Cr (30-09-2026)
Lock in: None
Scheme code (Direct): 152349
ISIN (Direct): INF03VN01886
Scheme code (Regular): 152348
ISIN (Regular): INF03VN01878
NAV history: From 07-02-2024, 2.7 years

Exit load: Nil

Tax on WhiteOak Capital Pharma and Healthcare Fund returns

WhiteOak Capital Pharma and Healthcare Fund is taxed as an equity fund: 65% or more of it is in Indian stocks.
Units sold within 1 year: the gain is taxed at 20%.
Units held longer: gains above ₹1.25 lakh in a financial year, across all your equity funds and shares, are taxed at 12.5%.
IDCW (dividend) payouts are added to your income and taxed at your slab rate.
A stamp duty of 0.005% is deducted when you invest.

Rules in force from 23-07-2024 (Finance Act 2024). Tax depends on your own income; this is general information, not tax advice.

All plans and options

Plan	Option	NAV	As on
direct	Growth	₹17.441	30-10-2026
regular	Growth	₹16.631	30-10-2026

About WhiteOak Capital Pharma and Healthcare Fund

WhiteOak Capital Pharma and Healthcare Fund is a mutual fund from WhiteOak Capital Mutual Fund. Its category is Sectoral. It was launched on 06-02-2024. Its benchmark is BSE Healthcare TRI. At the end of September 2026 it held 59 securities.

Fund Manager

Ramesh Mantri
Fund manager of WhiteOak Capital Pharma and Healthcare Fund, since 06-02-2024
Piyush Baranwal
Fund manager of WhiteOak Capital Pharma and Healthcare Fund, since 06-02-2024
Dheeresh Pathak
Fund manager of WhiteOak Capital Pharma and Healthcare Fund, since 06-02-2024
Ashish Agrawal
Fund manager of WhiteOak Capital Pharma and Healthcare Fund, since 06-01-2025
Trupti Agrawal
Fund manager of WhiteOak Capital Pharma and Healthcare Fund, since 20-05-2025

See all funds of WhiteOak Capital Mutual Fund

AUM change

September 2026: ₹926.55 Cr; +2.69% from August 2026
August 2026: ₹902.24 Cr; +9.38% from July 2026
July 2026: ₹824.90 Cr; +11.27% from June 2026

AUM moves with money invested or taken out, and with the value of what the fund holds.

Compare WhiteOak Capital Pharma and Healthcare Fund with Other Funds

Returns, risk, costs and the stocks they share, side by side

Compare with any other fund

Frequently Asked Questions for WhiteOak Capital Pharma and Healthcare Fund

What is the current NAV of WhiteOak Capital Pharma and Healthcare Fund?

The Direct plan NAV is ₹17.441. The Regular plan NAV is ₹16.631, as on 30-10-2026.

What are the returns of WhiteOak Capital Pharma and Healthcare Fund?

The Direct plan returned +19.53% in 1 year. The Regular plan returned +17.49% in 1 year. These figures are as on 30-10-2026.

What is the expense ratio of WhiteOak Capital Pharma and Healthcare Fund?

The Direct plan charges 1.07% a year. The Regular plan charges 2.75% a year. This is the figure the fund house reported to AMFI, in force from 23-10-2026.

What is the AUM of WhiteOak Capital Pharma and Healthcare Fund?

WhiteOak Capital Pharma and Healthcare Fund managed ₹926.55 Cr on 30-09-2026, as its fund house reported in its monthly portfolio.

What are the top holdings of WhiteOak Capital Pharma and Healthcare Fund?

At the end of September 2026 the largest holdings were DIVISLAB (8.36%), SUNPHARMA (7.11%), TORNTPHARM (6.26%), LAURUSLABS (3.91%), APOLLOHOSP (3.75%). The fund held 59 securities in all.

What did WhiteOak Capital Pharma and Healthcare Fund buy and sell in September 2026?

It bought 3 new stocks: Piramal Pharma Limited, Novartis India Limited, Mankind Pharma Limited. It sold out of 3: Cohance Lifesciences Limited, Pfizer Limited, Poly Medicure Limited. It added shares in 14. It reduced 4.

How do I invest in WhiteOak Capital Pharma and Healthcare Fund?

Through WhiteOak Capital Mutual Fund's website or app, a mutual fund distributor, or an investment platform. Choose the Direct plan to pay no distributor commission, or the Regular plan to invest through a distributor. The first investment is at least ₹500. You can invest once or through a monthly SIP.

Who is the fund manager of WhiteOak Capital Pharma and Healthcare Fund?

Ramesh Mantri (since 06-02-2024), Piyush Baranwal (since 06-02-2024), Dheeresh Pathak (since 06-02-2024), Ashish Agrawal (since 06-01-2025), Trupti Agrawal (since 20-05-2025).

Sources: NAV and expense ratio from AMFI. Holdings from the fund house's monthly portfolio statement. Fund facts from its scheme summary document, as on 16-10-2026.

This page is information, not investment advice. Mutual fund investments are subject to market risks; read all scheme related documents carefully. Past returns do not promise future returns. Figures come from AMFI, NSE, BSE and each fund house's own documents.